Winston Wong Tan MD FACP

[Pronunciation: FASCO]

Genitourinary Oncology, Hematologic Oncology, Melanoma

Professor of Medicine Mayo Clinic, Associate Dean continuous professional development Mayo Clinic, Past President Florida Society of clinical oncology Chair of Genitourinary Medical Oncology Past Program Director Hematology Oncology Fellowship

Join to View Full Profile

4500 San Pablo Road SJacksonville, FL 32224

Summary

Dr. Winston Tan is an oncologist in Jacksonville, FL and is affiliated with Mayo Clinic Hospital in Florida. He received his medical degree from University of Santo Tomas and has been in practice 31 years. He specializes in genitourinary oncology, hematologic oncology, and melanoma and is experienced in amyloidosis, hematologic oncology, testicular neoplasms, prostate cancer, and prostatitis.

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 2000
Maimonides Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Santo TomasClass of 1986

Certifications & Licensure

FL State Medical License 2000 - 2026
TX State Medical License 1994 - 2026
MI State Medical License 1994 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

FASCO American Society of Clinical Oncology, 2023

Clinical Trials

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 2
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 3
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Gene Expression in Patients with Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy Start of enrollment: 2013 May 30
ACTIVE_NOT_RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer Start of enrollment: 2022 Apr 04
RECRUITING
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik
Journal for Immunotherapy of Cancer. 2025-03-13
3 citations
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate canc...
Osama Mosalem, Winston Tan, Alan H Bryce, Roxana S Dronca, Daniel S Childs
Prostate Cancer and Prostatic Diseases. 2025-03-01
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane
Melanoma Research. 2024-12-01

Abstracts/Posters

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers
Winston Tan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019